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ABSTRACT
Whether reversible ischaemia in patients referred for exercise stress testing and MPI (myocardial
perfusion imaging) is associated with changes in circulating cTn (cardiac troponin) levels is
controversial. We measured cTnT with a sensitive assay before, immediately after peak exercise
and 1.5 and 4.5 h after exercise stress testing in 198 patients referred for MPI. In total, 19
patients were classiﬁed as having reversible myocardial ischaemia. cTnT levels were signiﬁcantly
higher in patients with reversible myocardial ischaemia on MPI at baseline, at peak exercise
and after 1.5 h, but not at 4.5 h post-exercise. In patients with reversible ischaemia on MPI,
cTnT levels did not change signiﬁcantly after exercise stress testing [11.1 (5.2–14.9) ng/l at
baseline compared with 10.5 (7.2–16.3) ng/l at 4.5 h post-exercise, P=0.27; values are medians
(interquartile range)]. Conversely, cTnT levels increased signiﬁcantly during testing in patients
without reversible myocardial ischaemia [5.4 (3.0–9.0) ng/l at baseline compared with 7.5 (4.6–
12.4)ng/l,P<0.001].Inconclusion,baselinecTnTlevelsarehigherinpatientswithMPIevidenceof
reversible myocardial ischaemia than those without reversible ischaemia. However, although cTnT
levels increase during exercise stress testing in patients without evidence of reversible ischaemia,
this response appears to be blunted in patients with evidence of reversible ischaemia. Mechanisms
other than reversible myocardial ischaemia may play a role for acute exercise-induced increases in
circulating cTnT levels.
INTRODUCTION
cTns (cardiac troponins) are the preferred biomarkers for
diagnosing acute MI (myocardial infarction). In patients
with ACS (acute coronary syndrome), increased levels
of cTns are associated with increased risk of death and
re-admissions, and identify patients who beneﬁt from
early, intensiﬁed treatment [1–3]. In patients with stable
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CAD (coronary artery disease), cTnT measured by a
highly sensitive assay is detectable in the large majority
of patients [4]. Interestingly, even levels below the 99th
percentile of a healthy reference population provide
prognostic information, and predict risk of mortality
and development of HF (heart failure), but not MI
[4]. The pathobiological mechanisms underlying cTn
release in patients without ACS are, however, unclear,
but reversible myocardial ischaemia may represent one
mechanism. Two previous studies have assessed the
proﬁle of circulating troponins during and after exercise
testing and the relationship to myocardial ischaemia,
but with diverging results. In one study, no change
in circulating cTnT was observed [5], whereas in
another study cTnI concentrations measured by a highly
sensitive assay increased in proportion to the severity
of myocardial ischaemia [6]. Whether these discrepant
results can be ascribed to biological differences between
cTnI and cTnT or differences in study population
composition are unclear.
In the present prospective study, we hypothesized
that cTnT levels measured with a sensitive assay would
increase more in patients with evidence of reversible
ischaemia on MPI (myocardial perfusion imaging) than
those without reversible ischaemia, and that, in patients
without reversible ischaemia, baseline levels of cTnT
would be higher in patients with a history of CAD than
those without such a history. In addition, we evaluated
the potential incremental diagnostic value of measuring
cTnTatbaselineandintherecoveryphasefordiagnosing
reversible ischaemia in patients with suspected CAD
referred to exercise stress testing and MPI.
MATERIALS AND METHODS
Patients
In total, 200 patients with chest pain and suspected
CAD referred for MPI at the Akershus University
Hospital were included in the ACE1 study (Akershus
CardiacExamination1study).Inclusionwasconsecutive
into three predeﬁned risk strata. Patients were classiﬁed
according to the probability of reversible myocardial
ischaemia (0–100%) by a cardiologist before testing.
We included 50 patients with low pre-test probability
(<33%), 100 patients with intermediate pre-test
probability (33–67%) and 50 patients considered to be
at high risk (>67% pre-test probability) of reversible
myocardial ischaemia. Exclusion criteria were, besides
contraindications to exercise testing of various causes
according to guidelines [7], age <18 and >80 years and
body weight >120 kg. Two patients were excluded due
todisseminatedmalignantdiseasediagnosedshortlyafter
the time of inclusion; thus the ﬁnal cohort comprised 198
patients. Information about co-morbidity, medication
andhistoryofCADwerecollectedfromhospitalrecords.
The ACE1 study was carried out in accordance with
the Declaration of Helsinki (2000) of the World Medical
Association, and was approved by the Regional Ethics
Committee.Writteninformedconsentwasobtainedfrom
all patients prior to study commencement.
Exercise stress test and MPI protocol
A stress–rest imaging protocol with a maximal bicycle
test was used for MPI. The ramp protocol of the stress
test started at 50 watt and increased by 10 watt/min.
The criterion for an adequate stress test was >85% of
the expected maximal HR [heart rate; 220−age (years)].
Symptoms, HR, BP (blood pressure) and a 12-lead ECG
wererecordedbeforethetest,midwaythrougheachstage
and during recovery. The stress test was terminated if
there was physical exhaustion, severe chest pain or other
symptoms of ACS, >2 mm horizontal or downsloping
ST-segment depression, 20 mmHg fall in systolic BP
or sustained ventricular arrhythmias. Duration of the
stress test, workload (Watts) achieved, peak HR and peak
BP were recorded. METs (metabolic equivalents) were
calculated using the equation:
METs = [12 × wordload(watt)
+300]/[weight(kg) × 3.5]
Results of the exercise stress test were determined by a
cardiologist and categorized as positive, intermediate or
negative based on symptoms and ECG alterations.
We administered 250–350 MBq (depending on body
weight) of 99mTc (technetium-99m)-tetrofosmin at peak
stress and the patient continued to exercise for at least
60 s after the injection. Stress imaging was performed
45 min after tracer administration. At 3–4 h later, 750–
900 MBq of 99mTc-tetrofosmin was injected at rest
and imaging was performed approximately 45 min after
tracer administration. SPECT (single-photon emission
computed tomography)-MPI was acquired using a
two-headed gamma camera (DST-XL; GE Healthcare
Technologies) equipped with a low-energy, high-
resolution collimator. Data were reconstructed into
short-axis, vertical long-axis and horizontal long-axis
slices, according to the individually determined anatomic
cardiac long axes. A 17-segment myocardial model
was used for semi-quantitative analysis, with a visual
perfusion rating of 0–4 for each segment, and the
summed stress score, SRS (summed rest score) and
summed difference score were calculated. Patients with
an SRS score 4 were considered to have signiﬁcant
ﬁxedperfusiondefectonMPI.Automaticallydetermined
semi-quantitative analysis of myocardial perfusion using
the commercially available software QPS (Quantitative
Perfusion Spect) was used as a supplement. The visual
perfusion rating was performed by a specialist in nuclear
medicineblindedtotroponindata.LVEF(leftventricular
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ejectionfraction)wascalculatedfromthegatedreststudy
using QGS (Quantitative Gated Spect) software.
Blood sampling and laboratory variables
An intravenous line was inserted in an antecubital vein
and blood samples were obtained before (baseline),
immediately after and 1.5 and 4.5 h after stress testing.
Blood samples were processed within 60 min after
collection, and stored at −80◦C until analysis. All
laboratory tests were performed by personnel blinded to
clinical information at the Clinical Chemistry laboratory
at Akershus University Hospital. cTnT was analysed
using a highly sensitive assay (Elecsys Troponin T hs
STAT assay; Roche Diagnostics). The limit of blank
of this assay is 3 ng/l, the assay 10% coefﬁcient of
variance threshold is 13 ng/l, and the 99th percentile
value in healthy subjects is 14 ng/l [8]. Serum creatinine
was analysed by a standard method, and the eGFR
(estimated glomerular ﬁltration rate) was estimated using
the Cockcroft–Gault formula [9].
Statistical analysis
Categorical variables are presented as proportions,
normally distributed continuous variables as means
and S.D. and non-normally distributed continuous
variables as medians and interquartile range (Q1–Q3).
A Kolmogorov–Smirnov test was used to determine
continuous variables were normally distributed. Baseline
characteristics were compared using χ2 test for
categorical variables, Student’s t test for normally
distributedvariables,andMann–WhitneyU testfornon-
normally distributed variables. cTnT values <3.0 ng/l
were assigned a value of 3.0 ng/l. To avoid that this
assignmentbluntedthevariationsofcTnTinpatientwith
low concentrations, we performed a subgroup analysis
in which patients with cTnT <3 ng/l at baseline were
excluded. The median differences between baseline and
post-stress test troponin levels were compared using
the Friedman test. The Wilcoxon signed rank test was
used to compare values between time points. Spearman
rank correlation analysis was performed to assess
associations between risk factors or indices of exercise
capacity and changes in cTnT level. To evaluate whether
cTnT measurements at baseline provided incremental
information for diagnosing myocardial ischaemia, we
assessed associations between baseline cTnT (log-
transformed) and reversible ischaemia in univariate and
multivariate logistic regression models. We adjusted for
the covariates age, sex, BMI (body mass index), eGFR,
LVEF, history of hypertension, history of CAD, history
of diabetes mellitus and results on exercise stress test.
A P<0.05 was considered statistically signiﬁcant except
for the Wilcoxon signed rank test where we applied a
Bonferroni corrected P value (P=0.05/3) due to multiple
testing. Statistical analyses were performed using SPSS
for Windows version 18.0.
RESULTS
Baseline characteristics
Characteristics of patients at baseline according to the
presenceorabsenceofreversiblemyocardialischaemiaon
MPIareshowninTable1.Intotal,19(10%)patientswere
classiﬁed as having reversible myocardial ischaemia. The
group of patients classiﬁed as being without reversible
ischaemia included both patients without evidence of
ischaemia (n=156) and patients with non-reversible
(ﬁxed) perfusion defects (n=23) on MPI. Overall, the
mean age was 60+ −11 years and 51% were female. The
patients with reversible myocardial ischaemia were more
likely to be male, to have a history of CAD and to
have lower LVEF. However, age, eGFR and BMI, as
well as cardiovascular risk factors such as hypertension,
diabetes mellitus and current smoking, did not differ
between patient groups. At stress testing, the patients
with reversible myocardial ischaemia had a median
(interquartile range) summed difference score of 4 (3–
5), whereas in patients without reversible ischaemia the
median(interquartilerange)summeddifferencescorewas
0 (0–1) (Table 2). Patients with reversible myocardial
ischaemia were more likely to have a positive stress test
(ECG) and to have lower peak HR.
cTnT proﬁle
Overall, cTnT, as measured by the highly sensitive assay,
was detectable (>3 ng/l) in serum samples from 145
(73%) patients at baseline. The 53 (27%) patients with
cTnT levels <3 ng/l at baseline (n=53) were younger
than those with higher levels, but the proportion of
women did not differ between patients with and without
detectablecTnTlevels(49comparedwith55%,P=0.51).
In total, 16 (8%) patients had no detectable cTnT at
any time point. The median (interquartile range) baseline
level in the total cohort was 6.2 (3.0–10.0) ng/l, and 27
(14%) patients had values at or above the 99th percentile
(14 ng/l) at baseline. After 4.5 h, the median cTnT level
in the entire cohort increased to 7.7 (4.9–13.4) ng/l
(P<0.001 compared with baseline).
Impact of the presence or absence of
reversible myocardial ischaemia
Whenpatientswerecategorizedaccordingtothepresence
(n=19) or absence (n=179) of reversible myocardial
ischaemia, differences in baseline levels and proﬁles
during and after exercise were observed. We found
cTnT levels to be signiﬁcantly higher in patients with
reversible myocardial ischaemia compared with those
without reversible myocardial ischaemia at baseline,
at peak exercise and at 1.5 h, but not at 4.5 h post-
exercise(Figure1).Inpatientswithreversiblemyocardial
ischaemia, cTnT levels declined from baseline [11.1
(5.2–14.9) ng/l] to peak exercise [8.6 (5.9–14.3) ng/l,
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Table 1 Baseline characteristics of the patients (n=198)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease.
Characteristic Total (n=198) Positive MPI (n=19) Negative MPI (n=179) P value
Troponin T (ng/l) 6.2 (3.0–10.0) 11.1 (5.2–14.9) 5.4 (3.0–9.2) 0.007
Troponin T <3 ng/l (n) 53 (27%) 4 (21%) 49 (27%) 0.79
Troponin T 14 ng/l (n) 27 (14%) 7 (37%) 20 (11%) 0.002
Demographics
Female 100 (51%) 3 (16%) 97 (54%) 0.001
Age (years) 60+ −11 63+ −12 59+ −11 0.12
Risk factors
BMI (kg/m2)2 7 + −42 8 + −32 7 + −40 . 1 3
Hypertension (n) 73 (37%) 11 (58%) 62 (35%) 0.052
Diabetes mellitus (n) 25 (13%) 4 (21%) 22 (12%) 0.29
Current smoking (n) 55 (28%) 4 (21%) 51 (29%) 0.60
Systolic BP (mmHg) 127+ −22 128+ −26 127+ −21 0.78
Diastolic BP (mmHg) 85+ −16 84+ −15 86+ −16 0.69
eGFR (ml/min) 97 (81–119) 97 (76–142) 99 (82–121) 0.69
LVEF 60 (54–69) 58 (51–64) 61 (55–69) 0.047
Pre-test probability (%) 60 (38–70) 60 (60–80) 50 (30–60) 0.008
Previous CAD (n)
History of CAD 77 (39%) 16 (84%) 61 (34%) <0.001
Documented MI 43 (22%) 10 (53%) 33 (19%) 0.001
Positive angiography 68 (34%) 16 (84%) 52 (30%) <0.001
History of PCI 55 (30%) 12 (63%) 43 (24%) <0.001
History of CABG 20 (10%) 5 (26%) 15 (9%) 0.031
History of COPD/asthma 25 (13%) 1 (5%) 24 (13%) 0.48
Medication (n)
Platelet aggregation inhibitor 118 (60%) 17 (89%) 101 (57%) 0.006
Lipid-lowering drug 111 (56%) 18 (95%) 93 (52%) <0.001
β-Blocker 92 (47%) 14 (74%) 78 (44%) 0.013
Diuretics 39 (20%) 8 (42%) 31 (17%) 0.010
Table 2 Results from the exercise stress test
Total (n=198) Positive MPI (n=19) Negative MPI (n=179) P value
Stress test performance
Positive stress test (ECG) 61 (31%) 10 (53%) 51 (29%) 0.030
Baseline heart rate (beats/min) 79 (69–90) 82 (71–90) 78 (69–91) 0.94
Peak heart rate (beats/min) 153 (144–164) 139 (134–155) 155 (146–165) 0.012
Percentage of maximal expected heart rate 95+ −89 1 + −99 5 + −8 0.060
Peak systolic BP (mmHg) 200 (174–211) 202 (182–208) 199 (174–212) 0.73
Peak diastolic BP (mmHg) 92 (81–106) 85 (70–110) 94 (82–106) 0.21
Duration (min) 8 (7–10) 9 (7–10) 8 (7–11) 0.36
Maximum strain (watts) 120 (100–140) 130 (108–133) 120 (100–150) 0.37
Maximum workload (METs) 7+ −26 + −17 + −20 . 1 5
MPI
Summed difference score 0 (0–1) 4 (3–5) 0 (0–1) <0.001
P=0.23], although this was not statistically signiﬁcant.
Changes from baseline to 1.5 h [8.6 (5.9–14.3) ng/l,
P=0.62] or from baseline to 4.5 h [10.5 (7.2–16.3)
ng/l, P=0.27] after exercise stress testing were also not
statistically signiﬁcant. Conversely, in patients without
reversible myocardial ischaemia, cTnT levels increased
from baseline [5.4 (3.0–9.0) ng/l] to 4.5 h after exercise
[7.5 (4.6–12.4) ng/l, P<0.001]. Excluding the 53 patients
with cTnT <3 ng/l at baseline did not substantially alter
the results.
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Figure 1 cTnT levels at different time points stratiﬁed by MPI results
The Table below shows the median (interquartile range) cTnT levels at the four different time points. P values in the Figure refer to changes in biomarker levels
across time points for each group. ∗P <0.05 for the comparison with the no reversible ischaemia group.
Impact of the presence or absence of
history of CAD
In patients without reversible ischaemia, levels of cTnT
were higher in patients with a history of CAD (n=61)
compared with no history of CAD (n=118) at all four
time points (Figure 2). Levels changed signiﬁcantly from
baseline [8.4 (4.2–11.4) ng/l] to 4.5 h [9.8 (6.6–14.9) ng/l,
P<0.001] in patients with a history of CAD, as well as
from baseline [4.8 (3.0–8.2) ng/l] to 4.5 h [6.3 (4.0–11.1)
ng/l, P<0.001] in patients without a history of CAD.
The magnitude of change was not different between the
two groups at any time point (Figure 2).
Impact of the presence or absence of
ﬁxed perfusion defects on MPI
In patients without reversible ischaemia, levels of cTnT
were higher in patients with ﬁxed perfusion defects
[n=23; 9.3 (4.1–13.9) ng/l] compared with those without
perfusion defects [n=156; 5.3 (3.0–8.7) ng/l] at baseline
(P=0.008),atpeakexercise[9.2(4.7–14.4)ng/lcompared
with 5.5 (3.1–8.9) ng/l, P=0.009], and at 1.5 h [8.3 (5.1–
13.6)ng/lcomparedwith6.0(3.3–9.7)ng/l,P=0.025]but
not at 4.5 h [9.8 (5.5–16.7) ng/l compared with 7.5 (4.4–
12.2) ng/l, P=0.27] after stress. Levels did not change
signiﬁcantly from baseline [9.3 (4.1–13.9) ng/l] to peak
stress[9.2(4.7–14.4)ng/l,P=0.84],to1.5 h[8.3(5.1–13.6)
ng/l, P=0.63] or to 4.5 h [9.8 (5.5–16.7) ng/l, P=0.24]
in patients with ﬁxed perfusion defects. However, in
patients without ﬁxed perfusion defects, cTnT levels
changed signiﬁcantly from baseline [5.3 (3.0–8.7) ng/l]
to 1.5 h [6.0 (3.3–9.7) ng/l, P=0.002] and 4.5 h [7.5 (4.4–
12.2) ng/l, P<0.001] after stress, but not to peak exercise
[5.5 (3.1–8.9) ng/l, P=0.54].
Variables correlated with a change in cTnT
The potential correlation between the change in cTnT
from baseline to 4.5 h post-exercise and cardiovascular
risk factors, including age, sex, eGFR, LVEF, history
of CAD, hypertension and diabetes mellitus, as well
as the MPI results, having a positive exercise stress
test (ECG) and indices of exercise capacity, including
maximumHRachieved,percentageofmaximalpredicted
HR, maximum work load (watts and METs) and exercise
duration, were assessed with correlation analysis. With
the exceptions of a weak correlation with the percentage
of maximal predicted HR achieved (Spearman ρ =0.16,
P=0.028)andaweaknegativecorrelationwithestimated
METs (ρ =−0.16, P=0.025), no signiﬁcant correlations
were observed.
Diagnostic value of cTnT to predict
reversible myocardial ischaemia
In univariate analysis, baseline log-transformed cTnT
levels were associated with having reversible myocardial
ischaemia {OR (odds ratio), 2.57 [95% CI (conﬁdence
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Figure 2 cTnT levels at different time points stratiﬁed by history of CAD in patients with negative MPI
The Table below shows median (interquartile range) cTnT levels at the four different time points in patients without reversible myocardial ischaemia( n=179).
P values in the Figure refer to changes in biomarker levels across time points for each group. ∗P <0.05 for the comparison with the no history of CAD group.
interval) 1.34–4.93); P=0.005}. After adjusting for age,
gender, BMI, eGFR, LVEF, history of CAD, diabetes
mellitus, hypertension and having a positive exercise
stress test, the association was no longer signiﬁcant [OR,
1.48 (95% CI, 0.52–4.22); P=0.46] (Table 3). Having a
history of CAD and a positive exercise stress test were
the only variables associated with reversible myocardial
ischaemia in multivariate analysis.
DISCUSSION
The main ﬁndings of the present study are that: (i)
cTnT levels are higher at baseline in patients with
reversible myocardial ischaemia than in patients without
reversible myocardial ischaemia, and (ii) cTnT levels
increase after exercise stress testing in patients without
reversible myocardial ischaemia, whereas this response
is blunted in patients with MPI evidence of reversible
myocardial ischaemia. Moreover, in patients without
reversible myocardial ischaemia, cTnT levels increase
during and after exercise stress testing regardless of the
presence or absence of a history of CAD, and although
baseline levels are higher in those with a history of CAD,
the magnitude of the cTnT increase is similar between
groups. Furthermore, similar to patients with reversible
perfusion defects, cTnT levels did not change in patients
with ﬁxed perfusion defects on MPI. Finally, baseline
levels of cTnT were higher in patients classiﬁed as having
reversible myocardial ischaemia during testing, but this
association was attenuated in multivariate models that
included standard clinical variables.
Whether reversible myocardial ischaemia is a stimulus
for troponin release to the circulation is controversial.
Cardiac troponins I and T are predominantly bound
to the contractile apparatus in cardiomyocytes, but a
minorfractionofthesemoleculesarefoundfreelysoluble
in the cytosol [10]. Recently, six different mechanisms
to explain how this fraction of troponins may be
released to the circulation in the absence of MI were
proposed [11]: (i) myocyte necrosis, (ii) apoptosis, (iii)
normal myocyte cell turnover, (iv) cellular release of
proteolytic troponin degradation products, (v) increased
cellular wall permeability and (vi) formation and release
of membranous blebs. Theoretically, the latter three
mechanisms may be stimulated by reversible myocardial
ischaemia. Observations from previous clinical studies
have, however, yielded diverging results. Kurz et al.
[5] found no change in cTnT levels measured by a
sensitive assay after stress testing, regardless of the
presence or absence of reversible coronary ischaemia
on MPI. Conversely, Sabatine et al. [6] reported that
cTnI measured with an ultrasensitive assay increased
in proportion to the degree of reversible myocardial
ischaemia 4 h after exercise stress testing. Our current
ﬁndings extend information from these prior studies by
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Table 3 Predictors of reversible ischaemia on MPI
DM, diabetes mellitus; HT, hypertension.
Univariate analysis Multivariate analysis
Parameter OR (95% CI) P value OR (95% CI) P value
Troponin T 2.57 (1.34–4.93) 0.005 1.48 (0.52–4.22) 0.46
Age 1.04 (0.99–1.08) 0.12 1.07 (0.96–1.18) 0.22
Gender (male) 6.31 (1.78–22.41) 0.00 3.15 (0.64–15.63) 0.16
BMI 1.09 (0.97–1.23) 0.14 1.11 (0.93–1.33) 0.23
eGFR 1.01 (0.99–1.02) 0.38 1.03 (0.99–1.06) 0.11
LVEF 0.97 (0.93–1.01) 0.12 1.00 (0.94–1.06) 0.88
History of CAD 10.32 (2.89–36.78) <0.001 16.15 (2.91–89.73) 0.001
History of DM 1.89 (0.58–6.21) 0.29 0.91 (0.20–4.26) 0.91
History of HT 2.53 (0.97–6.61) 0.06 3.37 (0.87–13.11) 0.08
Positive stress test (ECG) 2.79 (1.07–7.26) 0.04 7.49 (1.63–34.41) 0.01
demonstrating that baseline levels of cTnT are higher
in patients with reversible myocardial ischaemia than in
thosewithout,whereasexercisestresstestingisassociated
with a signiﬁcant increase in cTnT in the absence, but not
in the presence, of reversible myocardial ischaemia. The
latter observation is in direct contrast with our original
study hypothesis, but in accordance with very recent
data from a study in which patients with and without
angiographically signiﬁcant CAD underwent rapid atrial
pacing and coronary sinus sampling for assessment of
cTnT and lactate [12]. In that study, coronary sinus levels
of cTnT were higher at baseline in patients with CAD
than in patients without signiﬁcant CAD, but the relative
increase during and after atrial pacing appeared to be
largest in patients without signiﬁcant CAD.
Although baseline levels of cTnT were associated with
reversible myocardial ischaemia in a univariate logistic
regression model, this association was attenuated and no
longer signiﬁcant in multivariate analyses. Thus, it seems
unlikely that baseline cTnT measurements will be of any
practical clinical utility in the setting of exercise stress
testing for diagnosing reversible myocardial ischaemia.
As no increase in cTnT in proportion to reversible
myocardial ischaemia was observed in our study, it is also
unlikely that measurements in the recovery phase after
stress testing will be of any value in clinical practice. The
discrepancy with the ﬁndings of Sabatine et al. [6], who
observedanincreaseincTnIinproportiontotheextentof
myocardial ischaemia, raises the question whether there
is a difference between the two proteins in terms of
release from the cytosol. Free troponin I (molecular mass
of 22.5 kDa) is a smaller molecule than the free cTnT
(39 kDa), which could relate to a more dynamic release
of cTnI into the circulation. Alternative explanations
for the divergent results between our study and the
study of Sabatine et al. [6] include differences in patient
characteristics, including the proportion of patients with
positive MPI, and different analytical characteristics of
thetwotroponinassays.Thelargerproportionofpatients
with troponin levels below the detection limit in our
study compared with the study of Sabatine et al.[6] may
also have inﬂuenced results, although we ﬁnd similar
results after excluding the patients with undetectable
cTnT levels. Of note, as reported previously [13], there
was a higher prevalence of undetectable cTnT levels
among young subjects compared with elderly subjects,
while we did not see any difference due to gender.
Strengths and limitations
Thestrengthsofthepresentstudyincludetheprospective
design and well-characterized patient population, serial
blood sampling and the use of a highly sensitive cTnT
assay well suited to detect changes in circulating cTnT
levels. Limitations include 27% of the cohort having
undetectable levels of cTnT at baseline and 8% having
undetectable cTnT levels at any time point, which
precludes the detection of minor changes below 3 ng/l.
Thus an even more sensitive assay may have been able to
detect differences that were not picked up by the current
assay. Other limitations are the relatively modest number
of patients with reversible myocardial ischaemia and the
imperfection of MPI as reference standard for detecting
myocardial ischaemia.
Conclusions
In patients referred to MPI with exercise stress
testing, cTnT increases from baseline to 4.5 h after
stress testing in the absence of reversible myocardial
ischaemia, but not in patients with evidence of reversible
myocardial ischaemia, implying that mechanisms other
than reversible myocardial ischaemia may play a role in
the increase. Our ﬁndings indicate a need for further
clinical studies that include a larger number of patients
and a standardized protocol of sampling, in order to
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clarify the time course of cTnI and cTnT levels after
exercise stress in patients with and without CAD.
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